Euromedix a.s.

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Macular degeneration3 trials
• Diabetic eye disease2 trials

Phase

• Phase 34 trials
• Phase 2/31 trial

Status

• Recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• Alvotech Swiss AG1 trial
• Amgen1 trial
• Eyebiotech Limited1 trial
• Eyepoint Inc.1 trial
• EyePoint Pharmaceuticals, Inc.1 trial

Running trials

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Amgen· Source

• Active, not recruiting

  COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  2025-523937-25-00· Phase 3· Eyepoint Inc.· Source

• Recruiting

  Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema

  2025-522231-34-00· Phase 3· Alvotech Swiss AG· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration2 recruiting
• Diabetic eye disease1 recruiting